Dewey Steadman

Dewey Steadman, CFA, currently serves as the Head of Investor & Media Relations at United Therapeutics Corporation, a role held since 2019. Prior to this, Dewey was the Principal and Senior Specialty Pharmaceuticals Analyst at Canaccord Genuity Inc., leading a team that analyzed over 16 specialty pharmaceutical and biotechnology stocks. Previous experience includes serving as the Executive Director of Investor Relations at Akorn, Inc., and as Director of Investor Relations at Actavis plc, contributing to a team recognized by Institutional Investor and IR Magazine. Dewey's earlier roles include Vice President of US Pharmaceuticals at J.P. Morgan, Equity Research Associate at RBC Capital Markets, and various positions in investment analysis and portfolio management. Dewey holds an MBA in Finance and International Business from Crummer Graduate School of Business and a Certificate in Business Excellence from Columbia Business School.